Page last updated: 2024-11-08

4-methyl-2-quinazolinamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-methyl-2-quinazolinamine: from Streptomyces of TCM plant; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID269325
CHEMBL ID1441434
SCHEMBL ID377227
MeSH IDM0540077

Synonyms (27)

Synonym
4-methyl-2-quinazolinamine
NCGC00014114
nsc-110275
nsc110275 ,
6141-02-2
OPREA1_804244
NCI110275
NCI60_000243
NCISTRUC1_000219
NCISTRUC2_000138
NCGC00097223-01
STK023736
4-methylquinazolin-2-amine
CCG-37993
NCGC00014114-02
AKOS005379039
2-amino-4-methylquinazoline
RWDYNDCLJPWKJU-UHFFFAOYSA-N
mfcd03164950
SCHEMBL377227
CHEMBL1441434 ,
DTXSID10296593
EN300-7816608
FT-0766157
methyl-[amino]quinazoline
bdbm50241663
Z57166964

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID893
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency6.30960.011212.4002100.0000AID1030
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency3.54810.001815.663839.8107AID894
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)IC50 (µMol)5.60000.05201.20935.6000AID1452124
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
purine nucleoside catabolic process7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
DNA repair7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
response to oxidative stress7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
male gonad development7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
DNA protection7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
response to cadmium ion7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
5'-(N(7)-methylguanosine 5'-triphospho)-[mRNA] hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
protein binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
8-oxo-7,8-dihydroguanosine triphosphate pyrophosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
dATP diphosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
snoRNA binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
8-oxo-7,8-dihydrodeoxyguanosine triphosphate pyrophosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
metal ion binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
ATP diphosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
2-hydroxy-ATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
2-hydroxy-dATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
N6-methyl-(d)ATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
O6-methyl-dGTP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
acrosomal vesicle7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
extracellular space7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
nucleus7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytoplasm7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
mitochondrion7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
mitochondrial matrix7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytosol7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
nuclear membrane7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytoplasm7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1452124Inhibition of human recombinant His-tagged MTH1 expressed in Escherichia coli BL21 using dGTP as substrate after 15 mins by malachite green reagent-based assay2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space.
AID1917342Induction of read through activity at T-p53 R213X mutant premature termination codon in human HDQ-P1 cells assessed as increase in production of full length p53 protein by MSD assay2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Guanidino quinazolines and pyrimidines promote readthrough of premature termination codons in cells with native nonsense mutations.
AID1452123Inhibition of human recombinant His-tagged MTH1 expressed in Escherichia coli BL21 at 125 uM using dGTP as substrate after 1 hr by malachite green reagent-based assay relative to control2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.16 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]